IDYA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
IDEAYA Biosciences Inc (IDYA) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong positive catalysts, including upcoming clinical trial results, favorable analyst ratings, and a growing oncology pipeline. While the company is not yet profitable, its revenue growth and strategic milestones indicate potential for long-term gains.
The MACD is positive and expanding, indicating bullish momentum. RSI is neutral at 48.457, and moving averages are converging, suggesting consolidation. The stock is trading near its pivot level of 31.463, with resistance at 32.93 and support at 29.995.
Enrollment of the first patient in the Phase 1 trial for IDE034, triggering a $5 million milestone payment.
Appointment of Dr. Theodora Ross as Chief Development Officer to enhance the oncology pipeline.
Upcoming Phase 2/3 OptimUM-02 trial data expected in late March, which could be a major catalyst.
Analysts have consistently raised price targets, with Citi setting a target of $65 and RBC Capital at $60.
The company is not yet profitable, with a net income loss of -$83.27M in Q4
EPS dropped by -36.91% YoY, indicating financial challenges.
Short-term stock trend analysis shows a potential decline of -1.75% in the next week and -6.25% in the next month.
In Q4 2025, revenue increased by 55.37% YoY to $10.88M, indicating strong growth. However, net income dropped to -$83.27M, down -36.10% YoY, and EPS fell to -0.94, reflecting ongoing financial losses. Gross margin remains strong at 100%.
Analysts are overwhelmingly positive on IDYA, with multiple firms raising price targets recently. Citi has a target of $65, Wedbush at $52, RBC Capital at $45, UBS at $50, and Truist at $60. Analysts highlight strong Phase II data, upcoming catalysts, and an 85% probability of success in key trials.
